• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    7/17/23 1:31:11 PM ET
    $ABOS
    $APLS
    $ARGX
    $BBIO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABOS alert in real time by email

    Gainers

    • BridgeBio Pharma (NASDAQ:BBIO) shares rose 78.8% to $32.58 during Monday's regular session. The current volume of 37.7 million shares is 2024.4% of BridgeBio Pharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $5.2 billion.
    • Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 62.89% to $10.23. Acumen Pharmaceuticals's stock is trading at a volume of 25.2 million shares as of 13:30 EST. This is 8337.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $419.6 million.
    • Quantum-Si (NASDAQ:QSI) shares moved upwards by 33.91% to $3.24. The current volume of 10.6 million shares is 1409.2% of Quantum-Si's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $458.5 million.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) stock moved upwards by 28.91% to $7.0. The current volume of 3.4 million shares is 14598.6% of Lixte Biotech Hldgs's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $11.6 million.
    • argenx (NASDAQ:ARGX) shares increased by 27.33% to $482.69. The current volume of 2.0 million shares is 904.0% of argenx's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $27.0 billion.
    • Rockwell Medical (NASDAQ:RMTI) shares increased by 24.29% to $3.96. Trading volume for this security as of 13:30 EST is 3.3 million, which is 391.1% of its average full-day volume over the last 100 days. The company's market cap stands at $112.9 million.

    Losers

    • ViewRay (NASDAQ:VRAY) stock decreased by 78.5% to $0.08 during Monday's regular session. Trading volume for this security as of 13:30 EST is 109.1 million, which is 3593.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $14.3 million.
    • Novan (NASDAQ:NOVN) stock fell 69.64% to $0.19. Novan's stock is trading at a volume of 12.3 million shares as of 13:30 EST. This is 3622.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.1 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares declined by 29.31% to $0.04. Tivic Health Systems's stock is trading at a volume of 34.3 million shares as of 13:30 EST. This is 445.6% of its average full-day volume over the last 100 days. The company's market cap stands at $2.7 million.
    • Virios Therapeutics (NASDAQ:VIRI) shares fell 22.94% to $1.86. Virios Therapeutics's stock is trading at a volume of 1.6 million shares as of 13:30 EST. This is 59.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $34.1 million.
    • Apellis Pharmaceuticals (NASDAQ:APLS) shares fell 21.72% to $66.15. The current volume of 9.0 million shares is 580.3% of Apellis Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $7.7 billion.
    • Minerva Surgical (NASDAQ:UTRS) shares fell 17.3% to $0.25. As of 13:30 EST, this security is trading at a volume of 649.3K shares, making up 15.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $44.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS
    $APLS
    $ARGX
    $BBIO

    CompanyDatePrice TargetRatingAnalyst
    argenx SE
    $ARGX
    3/10/2026Hold → Buy
    Deutsche Bank
    BridgeBio Pharma Inc.
    $BBIO
    3/10/2026Outperform
    William Blair
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    1/21/2026$28.00Neutral → Buy
    BofA Securities
    BridgeBio Pharma Inc.
    $BBIO
    1/6/2026$96.00Overweight
    Morgan Stanley
    argenx SE
    $ARGX
    12/18/2025$858.00Outperform → Neutral
    Robert W. Baird
    BridgeBio Pharma Inc.
    $BBIO
    12/11/2025$94.00Outperform
    Bernstein
    More analyst ratings

    $ABOS
    $APLS
    $ARGX
    $BBIO
    SEC Filings

    View All

    SEC Form 144 filed by BridgeBio Pharma Inc.

    144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

    3/10/26 4:02:29 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    3/10/26 4:00:37 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    3/6/26 6:15:09 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $APLS
    $ARGX
    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

    Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

    5/17/21 11:09:40 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $APLS
    $ARGX
    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dowdy Paula bought $104,450 worth of shares (109,890 units at $0.95), increasing direct ownership by 69% to 269,107 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:13 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Kummeth Charles R. bought $459,800 worth of shares (500,000 units at $0.92), increasing direct ownership by 141% to 855,000 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:59 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:49:25 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $APLS
    $ARGX
    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

    NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid

    3/10/26 4:00:00 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Powell Max Limited Successfully Repositions for Its Next Phase of Growth

    Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (NASDAQ:PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following corporate update regarding its successful repositioning. Key Highlights: Raised $17 million in capital from new investorsAppointed new Chairman and Chief Executive Officer Geordan PursgloveReconstituted the Board of DirectorsRegained compliance with Nasdaq listing requirements Powell Max Chairman and Chief Executive Officer Geordan Pursglove commented, "My first month at Powell Max has been extremely productive. We successfully completed a corporate restructuring in a short timeframe, raised

    3/9/26 8:30:00 AM ET
    $ALBT
    $CISO
    $GRDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Professional Services
    Consumer Discretionary

    argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

    Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypesNew biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-f

    3/6/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $APLS
    $ARGX
    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    argenx upgraded by Deutsche Bank

    Deutsche Bank upgraded argenx from Hold to Buy

    3/10/26 3:28:52 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    William Blair initiated coverage on BridgeBio Pharma

    William Blair initiated coverage of BridgeBio Pharma with a rating of Outperform

    3/10/26 8:40:05 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on BridgeBio Pharma with a new price target

    Barclays initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $157.00

    1/28/26 7:16:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $APLS
    $ARGX
    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Acumen Pharmaceuticals Inc.

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    3/10/26 9:45:26 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Dowdy Paula bought $104,450 worth of shares (109,890 units at $0.95), increasing direct ownership by 69% to 269,107 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:13 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Kummeth Charles R. bought $459,800 worth of shares (500,000 units at $0.92), increasing direct ownership by 141% to 855,000 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:59 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $ABOS
    $APLS
    $ARGX
    $BBIO
    Financials

    Live finance-specific insights

    View All

    Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results

    Releases List Price of Proteus™ Platform Reiterates Proteus Development Program On Track for Year End 2026 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. Press Release Highlights Reported fourth quarter revenue of $451,000 Reported on track development of the Proteus platform and related R&D programs to expand proteome coverage and enable broad PTM analysis capabilities Announced list price for Proteus of $425,000 Announced 2026 Financial Guidance

    3/3/26 4:05:00 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET. WEBCAST DETAILS Date: Thursday, March 26, 2026 Time: 8:00am ET Webcast and Replay: www.RockwellMed.com/Results Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer Jesse Neri — SVP, Chief Financial Off

    2/26/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative ("seronegative") gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported f

    2/26/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $APLS
    $ARGX
    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    11/14/24 5:17:40 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $APLS
    $ARGX
    $BBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate